PubMed_ID,Title,Publication Date,Non Academic Author(s),Company Affiliations,Corresponding Author Email
40184452,MIST: An interpretable and flexible deep learning framework for single-T cell transcriptome and receptor analysis.,2025-Apr-04,None,"Department of Systems Biomedical Sciences, School of Medicine, Jinan University, Guangzhou 510632, China.",N/A
40183219,Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors.,2025-Apr-04,None,"Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.",N/A
40182622,Investigation of sphingolipid-related genes in lung adenocarcinoma.,2025,None,"Department of Radiation Oncology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.; Department of Radiation Oncology, The Affiliated Hospital of Nantong University, Nantong, China.; Cancer Institute of Traditional Chinese Medicine/Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.",N/A
40181976,Fatty acid metabolism-derived prognostic model for lung adenocarcinoma: unraveling the link to survival and immune response.,2025,None,"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.",N/A
40181964,Developing CAR-T/NK cells that target EphA2 for non-small cell lung cancer treatment.,2025,None,"Center for Gene & Cell Therapy, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.",N/A
40181378,Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy.,2025-Apr-03,None,"Department of Oncology, Pukou Branch of Jiangsu People's Hospital, Nanjing Pukou District Central Hospital, Nanjing, China.; Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.",rhguo@njmu.edu.cn
40180420,Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors.,2025-Apr-02,None,"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Aichi Prefecture, Japan.; Department of Immunology, Kindai University Faculty of Medicine Graduate School of Medical Sciences, sayama, Osaka, Japan.; Department of Immuno-Oncology, Kawasaki Medical School, Kurashiki, Japan.; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center-Hospital East, Kashiwa, Chiba, Japan.",hwada@gesurg.med.osaka-u.ac.jp
40180090,Human tripartite motif-containing protein 71 NCL-1/HT2A/LIN-41 domain crystal structure and its potential natural inhibitors.,2025-Apr-01,None,"Department of Hepatobiliary Surgery, Innovative Institute of Tumor Immunity and Medicine (ITIM), Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.; Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi 6205, Bangladesh.; Department of Biotechnology and Genetic Engineering, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh.; Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China; Ministry of Education Key Laboratory for Membraneless Organelles and Cellular Dynamics, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China; Hefei National Research Center for Cross-disciplinary Science, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.",N/A
40178843,Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.,2025-Apr-03,None,"Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf and German Hodgkin Study Group, Cologne, Germany.",N/A
40178661,Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors.,2025-Apr-03,None,"Department of Oncology, China Resources & Wisco General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, Hubei, China. 573514@qq.com.; Department of Oncology, China Resources & Wisco General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, Hubei, China.",2421100762@qq.com; 573514@qq.com; dr.qiutt@outlook.com
40177602,Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report.,2025,None,"Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.",N/A
40176898,Functional tumor-derived exosomes in NSCLC progression and clinical implications.,2025,None,"Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.; Department of Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.; Department of Abdominal Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.",N/A
40175986,The mediating effects of coping strategies between symptom clusters and quality of life in lung cancer patients undergoing immunotherapy.,2025-Apr-02,None,"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China. 543243202@qq.com.; Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.",543243202@qq.com
40175465,Localization of epidermal growth factor receptor-mutations using PNA:DNA probes in clinical specimens from patients with non-small cell lung cancer.,2025-Apr-02,None,"Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.; Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.; Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. y.akiyama@scchr.jp.",y.akiyama@scchr.jp
40175366,Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.,2025-Apr-02,None,"Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning, China. wangamandl@126.com.; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning, China. liujiwei@dmu.edu.cn.; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning, China.",wangamandl@126.com; liujiwei@dmu.edu.cn
40173379,Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First.,2025-Jun,None,"Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.; Department of Oncology, Queen's University, Kingston, Canada.",N/A
40172157,Advances in the treatment of KRAS,2025-Mar-15,None,"Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Medical Center, Clinical and Translational Research Fellowship, Pittsburgh, Pennsylvania, USA.",N/A
40171983,Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report.,2025-Apr-02,None,"Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey.",N/A
40171885,Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies.,2025-Mar-15,None,"Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.",N/A
40170983,"PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report.",2025-Apr,None,"Center For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Yale New-Haven Cancer Center, New Haven, Connecticut.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.",N/A
40170009,Integrative analysis of a novel signature incorporating metabolism and stemness-related genes for risk stratification and assessing clinical outcomes and therapeutic responses in lung adenocarcinoma.,2025-Apr-01,None,"Department of Medical Oncology, Huaihe Hospital of Henan University, Kaifeng, China.; Department of Immunology, School of Basic Medical Sciences, Henan University, Kaifeng, China. Lufeng@henu.edu.cn.; Department of Immunology, School of Basic Medical Sciences, Henan University, Kaifeng, China.",Lufeng@henu.edu.cn
40169071,Development and Preclinical Evaluation of a Gallium-68 Labeled Novel Diagnostic Tracer for Visualizing ALK Expression in Tumor.,2025-Mar-30,None,"Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.; Anhui province key laboratory of tumor immune microenvironment and immunotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.. Electronic address: daipf57@mail.ustc.edu.cn.",sihw@163.com; zhuh577@126.com; daipf57@mail.ustc.edu.cn
40167945,3'-deoxy-3'-,2025-Apr-01,None,"Department of Radiology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.; Department of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan. umeda@u-fukui.ac.jp.; Department of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.",umeda@u-fukui.ac.jp
40166933,ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer.,2025-Apr-01,None,"Department of Pathology and Frontier Innovation Center, School of Basic Medical Sciences, Fudan University, Shanghai, China.; Department of Immunology, School of Basic Medical Sciences, and MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, Fudan University, Shanghai, China.; Shanghai Fifth People's Hospital, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.",N/A
40165973,T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H.,2025,"Anja Dröge (HSDiagnomics GmbH, Berlin, Germany.); Sigrid Schaper (HSDiagnomics GmbH, Berlin, Germany.); Kristin Gennermann (HSDiagnomics GmbH, Berlin, Germany.); Nadine Genzel (TheryCell GmbH, Berlin, Germany.); Stephanie Plassmann (TheryCell GmbH, Berlin, Germany.); David Weismann (Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria.); Samuel W Lukowski (Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria.); Dominik Bents (TheryCell GmbH, Berlin, Germany.); Volkhard Seitz (HSDiagnomics GmbH, Berlin, Germany.); Rudolf Hammer (HSDiagnomics GmbH, Berlin, Germany.); Paul J Adam (Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria.); Steffen Hennig (HSDiagnomics GmbH, Berlin, Germany.)","Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria.; TheryCell GmbH, Berlin, Germany.; HSDiagnomics GmbH, Berlin, Germany.",N/A
40165937,Exploring the oncogenic role and prognostic value of ,2025,None,"Department of Biotechnology and Genetic Engineering, Faculty of Life Sciences, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh.; Department of Genetic Engineering and Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chattogram, Bangladesh.; Biotechnology Program, Department of Mathematics and Natural Sciences, School of Data and Sciences, BRAC University, Dhaka, Bangladesh.; Department of Biochemistry and Biotechnology, Faculty of Bio-Sciences, University of Barishal, Barishal, Bangladesh.; Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, Jahangirnagar University, Dhaka, Bangladesh.; Department of Biotechnology, Bangladesh Agricultural University, Dhaka, Bangladesh.; Department of Genetic Engineering and Biotechnology, School of Life Sciences, Shahjalal University of Science and Technology, Sylhet, Bangladesh.",N/A
40165352,Early-Onset COPD and Lung Cancer: Case Studies Highlighting Diagnostic Challenges in Younger Patients.,2025-Apr-01,None,"Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy, Warsaw, Poland.",N/A
40163162,Identification of a long non-coding RNA signature associated with cuproptosis for prognosis and immunotherapy response prediction in patients with lung adenocarcinoma.,2025-Mar-31,None,"State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.",eyxiejianjiang@scut.edu.cn; eyxiaogang@scut.edu.cn
40162997,Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis.,2025-Apr-02,None,"Department of Medical Oncology, Shanghai Pulmonary Hospital, Cancer Institute, Tongji University School of Medicine, Shanghai, China.",N/A
40162549,Transitional CXCL14,2025-Apr,None,"Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.",N/A
40162076,The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy.,2025,None,"Department of Pharmacy, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.",N/A
40160297,Treatment of advanced‑stage non‑small cell lung cancer: Current progress and a glimpse into the future (Review).,2025-May,None,"Department of Integrative Medicine and Medical Oncology, Shengzhou People's Hospital (Shengzhou Branch of The First Affiliated Hospital of Zhejiang University School of Medicine, Shengzhou Hospital of Shaoxing University), Shengzhou, Zhejiang 312400, P.R. China.; Department of Oncology Radiotherapy, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, Shaoxing, Zhejiang 311800, P.R. China.",N/A
40159631,Machine Learning Unveils Sphingolipid Metabolism's Role in Tumour Microenvironment and Immunotherapy in Lung Cancer.,2025-Apr,None,"Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.",N/A
